Drug Profile
MMI 0100 - Moerae Matrix
Alternative Names: MMI-0100Latest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator Moerae Matrix
- Class Anti-inflammatories; Antifibrotics; Peptides
- Mechanism of Action MAP-kinase-activated kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Fibrosis; Idiopathic pulmonary fibrosis
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for phase-I development in Idiopathic-pulmonary-fibrosis(In volunteers) in Netherlands (Inhalation)
- 28 Jul 2020 No recent reports of development identified for phase-I development in Idiopathic-pulmonary-fibrosis(In volunteers) in United Kingdom (Inhalation)
- 20 May 2018 Pharmacodynamics data from a phase I trial in Idiopathic pulmonary fibrosis presented at the 114th International Conference of the American Thoracic Society (ATS-2018)